Alnylam Pharmaceuticals ALNY
NASDAQ ALNY
$255.36 -0.60 (-0.23%)
At close: Sep 28, 2026 · 4:00 PM EDT

Alnylam Pharmaceuticals (ALNY) Non Operating Interest Expenses (2020 - 2026)

Updated

Alnylam Pharmaceuticals' Non Operating Interest Expenses was $82.05 million in Q2 2026, up 33.5% from $61.46 million a year earlier and up 18.4% from the prior quarter.

Analysis

Alnylam Pharmaceuticals (ALNY) Non Operating Interest Expenses (2020 - 2026) Analysis & Trends

On a trailing twelve-month basis, Alnylam Pharmaceuticals' Non Operating Interest Expenses was $261.14 million through Jun 30, 2026, up 35.2% year-over-year; for FY2025, it came in at $252.63 million, up 78.1% from FY2024.

  • Non Operating Interest Expenses shows a five-year compound annual growth rate of 24.5% (FY2020 to FY2025).
  • In earlier years, Non Operating Interest Expenses was $141.86 million in FY2024 (+17.0%), $121.22 million in FY2023 (-22.3%), $155.97 million in FY2022 (+9.1%) and $143.02 million in FY2021 (+69.3%).
  • The Q2 2026 figure marks the highest quarterly Non Operating Interest Expenses in data going back to Q2 2020.
  • Compared with a year earlier, Non Operating Interest Expenses has increased for 11 straight quarters, with growth averaging 41.9% over the last eight quarters.
  • The best year-over-year quarter for Non Operating Interest Expenses over five years was Q2 2025 (growth of 84.8%); the worst was Q1 2023 (a decline of 31.6%).
  • Per Business Quant data, ALNY's Non Operating Interest Expenses in the three quarters before Q2 2026 was $69.29 million (Q1 2026), $65.4 million (Q4 2025) and $44.4 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Johnson & Johnson 653.54 Bn 572.07 Bn 17.26 Bn 281.00 Mn
2 AbbVie 467.01 Bn 440.17 Bn 12.70 Bn -
3 Merck 367.16 Bn 321.59 Bn 12.21 Bn -
4 Novartis Ag 277.56 Bn 233.43 Bn 11.24 Bn -462.00 Mn
5 Astrazeneca 258.23 Bn 231.79 Bn 12.86 Bn -435.00 Mn
6 Amgen 224.14 Bn 179.54 Bn 7.24 Bn 673.00 Mn
7 Gilead Sciences 187.30 Bn 161.42 Bn 6.22 Bn 247.00 Mn
8 Pfizer 163.47 Bn 110.41 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 133.31 Bn 105.31 Bn 2.84 Bn -
10 Alnylam Pharmaceuticals 34.23 Bn 22.28 Bn 992.69 Mn 82.05 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 82.05 Mn
Mar 31, 2026 69.29 Mn
Dec 31, 2025 65.40 Mn
Sep 30, 2025 44.40 Mn
Jun 30, 2025 61.46 Mn
Mar 31, 2025 58.31 Mn
Dec 31, 2024 38.97 Mn
Sep 30, 2024 34.38 Mn
Jun 30, 2024 33.26 Mn
Mar 31, 2024 35.25 Mn
Dec 31, 2023 31.34 Mn
Sep 30, 2023 30.89 Mn
Jun 30, 2023 30.04 Mn
Mar 31, 2023 28.96 Mn
Dec 31, 2022 29.91 Mn
Sep 30, 2022 41.08 Mn
Jun 30, 2022 42.61 Mn
Mar 31, 2022 42.36 Mn
Dec 31, 2021 36.82 Mn
Sep 30, 2021 40.27 Mn
API Access

Alnylam Pharmaceuticals Non Operating Interest Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-operating-interest-expenses&ticker=ALNY&period=max&api_key=YOUR_API_KEY